Pfizer and Valneva Begins Phase 3 Trial of Lyme Disease Vaccine
Pfizer Inc. and Valneva has announced the beginning of a Phase 3 clinical study of Vaccine Against Lyme for Outdoor Recreationists (VALOR), to investigate the safety, efficacy, and immunogenicity of the investigational Lyme disease vaccine candidate known as VLA15. Annaliesa Anderson, senior vice president and head of vaccine research and development at Pfizer, said with […]
Continue Reading